Results 181 to 190 of about 26,004 (264)

Efficacy and Safety of DNV3 (a Lymphocyte‐activation Gene 3–blocking Antibody) Combined With Toripalimab and Chemotherapy in Advanced Melanoma: An Open‐label, Single‐arm Clinical Trial

MedComm, Volume 7, Issue 3, March 2026.
This investigator‐initiated trial demonstrates that LAG‐3/PD‐1 dual blockade (DNV3 + toripalimab) combined with chemotherapy achieves a 44.4% overall response rate (ORR) in advanced melanoma, showing particular efficacy in anti‐PD‐(L)1‐resistant patients (42.9% ORR, 7.36‐month median PFS), treatment‐naïve mucosal melanoma (50.0% ORR), and those with ...
Jing Lin, Lizhu Chen, Ling Chen, Dingyi Wang, Yuping Lu, Huishan Zhang, Ping Chen, Wei Yan, Zuoxiang Xiao, Yu Chen   +9 more
wiley   +1 more source

Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydroxychloroquine/ipilimumab in untreated metastatic pancreatic adenocarcinoma. [PDF]

J Immunother Cancer
O'Reilly EM, Cabanski CR, Lyman JP, Wainberg ZA, Fisher GA, Wolff RA, Ko AH, O'Hara MH, Spencer CN, Yu JX, Da Silva DM, Padrón LJ, Arnott J, Fairchild J, Moore JS, Peng B, Hoos WA, O'Donnell-Tormey J, Boffo S, Dugan U, Kimmelman AC, Amaravadi RK, Vonderheide RH.   +22 more
europepmc   +1 more source

Chromatin Accessibility in Cancer: Biological Functions, Mechanisms, Therapeutic Potential, and Future Directions

MedComm, Volume 7, Issue 3, March 2026.
Cancer remains the leading cause of mortality worldwide, and drug resistance further underscores the urgent need for innovative therapeutic strategies. Chromatin, a stable yet highly dynamic nucleoprotein complex, serves as the primary carrier of genetic material in eukaryotic cells.
Wentao Xia, Min Jiang, Yefei Huang, Kun Ding, Yansu Chen   +4 more
wiley   +1 more source

Nab-paclitaxel plus bevacizumab for patients with metastatic extrapulmonary neuroendocrine carcinoma: a phase 2 single-arm study. [PDF]

EClinicalMedicine
Zhang P, Li S, Jia R, Hao J, Chen C, Gan S, Li J, Shen L, Lu M.   +8 more
europepmc   +1 more source

Local Anesthetics in Cancer: Mechanisms and Translational Perspectives

MedComm – Oncology, Volume 5, Issue 1, March 2026.
Local anesthetics demonstrate multifaceted antitumor effects that collectively contribute to cancer suppression. Beyond canonical sodium channel blockade, these agents exert the following pharmacological actions: inhibition of tumor cell proliferation, suppression of migration and invasion, induction of proapoptotic pathways, attenuation of ...
Wan‐li Wang, Tu Huang, Yi‐hang Hao, Min Zheng, Xin‐hua Liang   +4 more
wiley   +1 more source

Neoadjuvant BMS-813160, Nivolumab, Gemcitabine, and Nab-Paclitaxel for Patients with Pancreatic Cancer. [PDF]

Clin Cancer Res
Grierson PM, Wolf C, Suresh R, Wang-Gillam A, Tan BR, Ratner L, Oppelt P, Aranha O, Frith A, Pedersen KS, Spann J, Boice N, Brown A, Baer JM, Butka EG, Ahmad F, Xu Y, Liu J, DeNardo DG, Lim KH.   +19 more
europepmc   +1 more source

Targeting Tumor Dormancy and Recurrence: Molecular Mechanisms and Peptide Therapeutic Delivery

MedComm – Oncology, Volume 5, Issue 1, March 2026.
This review summarizes the molecular mechanisms that regulate tumor dormancy and its role in cancer recurrence, with emphasis on immune evasion, extracellular matrix remodeling, metabolic regulation and angiogenic switching. It further discusses emerging peptide–based therapeutic strategies aimed at detecting, modulating, and eliminating dormant tumor ...
Abdur Raheem Aleem, Atif Ali, Wajid Ali, Yuying Cheng, Zhibin Yan, Chaoyi Xia, Chenguang Liu, Caiyun Fu, Yiren Hu, Xi Wang   +9 more
wiley   +1 more source

Factors associated with taxane-associated acute pain syndrome in pancreatic cancer patients receiving gemcitabine and nab-paclitaxel. [PDF]

Discov Oncol
Saito Y, Takekuma Y, Komatsu Y, Sugawara M.   +3 more
europepmc   +1 more source

Aging‐Derived Alterations in Genomic, Immune, and Metabolic Networks: Implications for Cancer Development and Therapy

MedComm – Oncology, Volume 5, Issue 1, March 2026.
Ageing acts as a double‐edged sword in cancer. In the elderly, open chromatin, immunosenescence, and chronic inflammation drive SASP (IL‐6, MMPs), MDSC accumulation and T‐cell suppression, fostering tumor‐promoting microenvironments and limited therapeutic benefit.
Qi Wang, Xue Sun, Xinhao Han, Xingda Zhang, Wenzheng Wang, Hongbin Wang, He Ren, Lina Gu   +7 more
wiley   +1 more source

Response to Corcept's retraction request on manuscript of "Relacorilant plus nab-paclitaxel for recurrent, platinum-resistant ovarian cancer: a cost-effectiveness study". [PDF]

J Gynecol Oncol
Xu Q.
europepmc   +1 more source